These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12745671)

  • 1. Omapatrilat, an angiotensin-converting enzyme and neutral endopeptidase inhibitor, attenuates early atherosclerosis in diabetic and in nondiabetic low-density lipoprotein receptor-deficient mice.
    Levy Z; Dvir A; Shaish A; Trestman S; Cohen H; Levkovietz H; Rhachmani R; Ravid M; Harats D
    Int J Exp Diabesity Res; 2003; 4(1):59-64. PubMed ID: 12745671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice.
    Arnal JF; Castano C; Maupas E; Mugniot A; Darblade B; Gourdy P; Michel JB; Bayard F
    Atherosclerosis; 2001 Apr; 155(2):291-5. PubMed ID: 11254898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice.
    Jandeleit-Dahm K; Lassila M; Davis BJ; Candido R; Johnston CI; Allen TJ; Burrell LM; Cooper ME
    J Hypertens; 2005 Nov; 23(11):2071-82. PubMed ID: 16208151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of renin-angiotensin axis inhibition on early atherogenesis in LDL-receptor-deficient mice.
    Sharabi Y; Grossman E; Sherer Y; Shaish A; Levkovitz H; Bitzur R; Harats D
    Pathobiology; 2000; 68(6):270-4. PubMed ID: 11493760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of omapatrilat in low, normal, and high renin experimental hypertension.
    Trippodo NC; Robl JA; Asaad MM; Fox M; Panchal BC; Schaeffer TR
    Am J Hypertens; 1998 Mar; 11(3 Pt 1):363-72. PubMed ID: 9544878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omapatrilat decreased macrophage oxidative status and atherosclerosis progression in atherosclerotic apolipoprotein E-deficient mice.
    Hayek T; Hamoud S; Keidar S; Pavlotzky E; Coleman R; Aviram M; Kaplan M
    J Cardiovasc Pharmacol; 2004 Jan; 43(1):140-7. PubMed ID: 14668580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive and antihypertrophic effects of omapatrilat in SHR.
    Burrell LM; Droogh J; Man in't Veld O; Rockell MD; Farina NK; Johnston CI
    Am J Hypertens; 2000 Oct; 13(10):1110-6. PubMed ID: 11041166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats.
    Grönholm T; Cheng ZJ; Palojoki E; Eriksson A; Bäcklund T; Vuolteenaho O; Finckenberg P; Laine M; Mervaala E; Tikkanen I
    Eur J Pharmacol; 2005 Sep; 519(3):267-76. PubMed ID: 16137672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Peroxisome proliferator-activated receptor α/γ agonist tesaglitazar stabilizes atherosclerotic plaque in diabetic low density lipoprotein receptor knockout mice].
    Zhang BC; Li XK; Che WL; Li WM; Hou L; Wei YD; Xu YW
    Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Feb; 41(2):143-9. PubMed ID: 23710746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined neutral endopeptidase inhibitors.
    Cuculi F; Erne P
    Expert Opin Investig Drugs; 2011 Apr; 20(4):457-63. PubMed ID: 21323474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).
    Packer M; Califf RM; Konstam MA; Krum H; McMurray JJ; Rouleau JL; Swedberg K
    Circulation; 2002 Aug; 106(8):920-6. PubMed ID: 12186794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attenuation of early atherogenesis in low-density lipoprotein receptor-deficient mice by proteasome inhibition.
    Wilck N; Fechner M; Dreger H; Hewing B; Arias A; Meiners S; Baumann G; Stangl V; Stangl K; Ludwig A
    Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1418-26. PubMed ID: 22516063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice.
    Candido R; Jandeleit-Dahm KA; Cao Z; Nesteroff SP; Burns WC; Twigg SM; Dilley RJ; Cooper ME; Allen TJ
    Circulation; 2002 Jul; 106(2):246-53. PubMed ID: 12105166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential tissue and enzyme inhibitory effects of the vasopeptidase inhibitor omapatrilat in the rat.
    Kubota E; Dean RG; Hubner RA; Casley DJ; Johnston CI; Burrell LM
    Clin Sci (Lond); 2003 Sep; 105(3):339-45. PubMed ID: 12741953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasopeptidase inhibition in a canine model of exercise-induced left ventricular dysfunction.
    Holzgrefe HH; Arthur SR; Powell JR
    Clin Exp Pharmacol Physiol; 2002 Aug; 29(8):696-703. PubMed ID: 12100002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omapatrilat limits infarct size and lowers the threshold for induction of myocardial preconditioning through a bradykinin receptor-mediated mechanism.
    Ebrahim Z; Baxter GF; Yellon DM
    Cardiovasc Drugs Ther; 2004 Mar; 18(2):127-34. PubMed ID: 15162074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406.
    Sulpizio AC; Pullen MA; Edwards RM; Louttit JB; West R; Brooks DP
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1306-13. PubMed ID: 16144980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril.
    Trippodo NC; Fox M; Monticello TM; Panchal BC; Asaad MM
    J Cardiovasc Pharmacol; 1999 Dec; 34(6):782-90. PubMed ID: 10598120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice.
    Ebrahimian TG; Tamarat R; Clergue M; Duriez M; Levy BI; Silvestre JS
    Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):65-70. PubMed ID: 15528473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.